Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 3 Thyroid Cancer, Papillary 2 Sarcoma 2 Salivary Gland Neoplasms 2 Neoplasm Metastasis 2 Glioma 2 Central Nervous System Neoplasms 2 Wilms Tumor 1 Solid Tumors 1 Sarcoma, Ewing 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Nephroma, Mesoblastic 1 Neoplasms 1 Melanoma 1 Medulloblastoma 1 Lymphoma, Large-Cell, Anaplastic 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1

Interventions

pembrolizumab 36 Bevacizumab 25 Cyclophosphamide 23 Blood Specimen Collection 19 Nivolumab 17 Standard of Care 15 Carboplatin 15 Paclitaxel 14 atezolizumab 13 Gemcitabine 13 Exercise 13 Pemetrexed 11 Fluorouracil 11 Doxorubicin 11 Cisplatin 11 Cetuximab 10 Radiotherapy 9 Oxaliplatin 9 Magnetic Resonance Spectroscopy 9 Leucovorin 9 Docetaxel 9 130-nm albumin-bound paclitaxel 9 durvalumab 8 abemaciclib 8 Temozolomide 8 Surveys and Questionnaires 8 Rituximab 8 Prednisone 8 Biopsy 8 olaparib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × entrectinib × 90 days × Clear all

NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡